NASDAQ:MESO Mesoblast (MESO) Stock Price, News & Analysis $15.13 +0.26 (+1.75%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$15.12 -0.01 (-0.07%) As of 09/18/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Mesoblast Stock (NASDAQ:MESO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mesoblast alerts:Sign Up Key Stats Today's Range$14.83▼$15.2850-Day Range$14.12▼$18.2452-Week Range$13.05▼$21.50Volume214,720 shsAverage Volume182,560 shsMarket Capitalization$1.97 billionP/E RatioN/ADividend YieldN/APrice Target$39.00Consensus RatingHold Company Overview Mesoblast Limited (NASDAQ: MESO) is a biotechnology company focused on developing and commercializing regenerative medicine products based on proprietary mesenchymal lineage stromal cells. The company’s cell therapies are designed to address serious inflammatory and immune-mediated conditions by potentially reducing inflammation, supporting tissue repair and modulating immune responses. Mesoblast’s lead product, remestemcel-L, is marketed in the United States as Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. The therapy received approval from the U.S. Food and Drug Administration in 2024 and is the company’s first commercial product in the United States. Mesoblast has also investigated cell-based therapies for conditions including chronic heart failure, chronic low back pain and other inflammatory disorders. Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast has conducted research and clinical development activities in the United States, Australia and other international markets. The company’s products and candidates have been developed through internal research programs and collaborations with pharmaceutical and healthcare organizations. Mesoblast is led by founder and Chief Executive Officer Silviu Itescu, who has overseen the company’s development of allogeneic cellular medicines.AI Generated. May Contain Errors. Read More Mesoblast Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreMESO MarketRank™: Mesoblast scored higher than 30% of companies evaluated by MarketBeat, and ranked 751st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingMesoblast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialMesoblast has a consensus price target of $39.00, representing about 157.8% upside from its current price of $15.13.Amount of Analyst CoverageMesoblast has only been the subject of 2 research reports in the past 90 days.Read more about Mesoblast's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mesoblast are expected to grow in the coming year, from ($0.05) to $0.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -54.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -54.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.00% of the float of Mesoblast has been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 13.49, which indicates bearish sentiment.Change versus previous monthShort interest in Mesoblast has recently increased by 4.92%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.43% of the stock of Mesoblast is held by institutions.Read more about Mesoblast's insider trading history. Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MESO Stock News HeadlinesWhy brokers see 85% upside for this ASX biotech stockSeptember 4, 2026 | msn.comExperts tip these $3 billion ASX shares to deliver over 75% returnsSeptember 1, 2026 | msn.com“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days. | Chaikin Analytics (Ad)Mesoblast Limited (MESO) Q4 2026 Earnings Call TranscriptAugust 27, 2026 | seekingalpha.comMesoblast Reports Substantial Revenue Growth to US$120MAugust 26, 2026 | globenewswire.comMesoblast earnings: Strong revenue growth and operational milestones in FY26August 26, 2026 | msn.comMesoblast to Outline 2026 Results and Pipeline Progress in Investor WebcastAugust 24, 2026 | tipranks.comMesoblast Issues 875,000 Unquoted Employee Incentive OptionsAugust 24, 2026 | tipranks.comSee More Headlines MESO Stock Analysis - Frequently Asked Questions How have MESO shares performed this year? Mesoblast's stock was trading at $18.04 at the beginning of the year. Since then, MESO shares have decreased by 16.1% and is now trading at $15.13. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) posted its quarterly earnings data on Friday, July, 31st. The company reported ($0.07) earnings per share (EPS) for the quarter. The company earned $34.45 million during the quarter. When did Mesoblast's stock split? Mesoblast's stock reverse split before market open on Friday, January 5th 2024.The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. When did Mesoblast IPO? Mesoblast (MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. Who are Mesoblast's major shareholders? Top institutional shareholders of Mesoblast include Squarepoint Ops LLC (0.01%), Tobias Financial Advisors Inc. (0.01%) and GAMMA Investing LLC (0.01%). View institutional ownership trends. How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings7/31/2026Today9/20/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MESO's financial health is in the Green zone, according to TradeSmith. MESO has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees108Year Founded2004Price Target and Rating Average Price Target for Mesoblast$39.00 High Price Target$39.00 Low Price Target$39.00 Potential Upside/Downside+157.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.19 Current Ratio2.43 Quick Ratio2.09 Sales & Book Value Annual Sales$120.25 million Price / Sales16.34 Cash FlowN/A Price / Cash FlowN/A Book Value$4.38 per share Price / Book3.45Miscellaneous Outstanding Shares129,880,000Free Float105,459,000Market Cap$1.97 billion OptionableOptionable Beta2.12 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:MESO) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
